Clinical Trial Update: BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study comparing a fixed-dose combination tablet of saxagliptin 5 mg and metformin XR 500 mg to co-administered Saxagliptin 5 mg and Metfo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glifage XR (metformin hydrochloride XR)
• Onglyza (Saxagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 1 | Status: WITHDRAWN